KRISTINE SZABO: Open Payments
NPI 1326772518 · BRIDGEPORT, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,513 in 149 payments from 25 companies in 2025. Trend: 2023 $0 · 2024 $1,121 · 2025 $4,513
Food & beverage: $4,513
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 17 | $556 |
| AstraZeneca Pharmaceuticals LP | 11 | $517 |
| Alnylam Pharmaceuticals Inc. | 14 | $487 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 12 | $361 |
| Amgen Inc. | 12 | $346 |
| Lilly USA, LLC | 4 | $285 |
| BridgeBio Pharma, Inc. | 6 | $247 |
| ABBVIE INC. | 5 | $210 |
| Bayer Healthcare Pharmaceuticals Inc. | 9 | $206 |
| Corcept Therapeutics | 4 | $172 |
Products named: JARDIANCE, Wegovy, AMVUTTRA, Repatha, Attruby, AIRSUPRA, FARXIGA, Kerendia.
Industry payments across CT — which companies pay providers there.
